Women’s Health Diagnostic Test Market Application, Types, Growth Analysis and Business Value on Key Companies Development Strategies and Industry Trends with Status and Prospect 2019 – 2026
According to the World Health Organization (WHO), around 570,000 women died due to breast cancer in 2015. Moreover, according to the Centers for Disease Control and Prevention (CDC), around 236,968 women were diagnosed with breast cancer, among which around 41,211 women died in 2014. The data indicates a growing prevalence of chronic diseases among women. Growing demand for early stage diagnosis of infection/diseases requires new rapid diagnostic tests and imaging systems which is expected to fuel growth of the women’s health diagnostic test market in the near future.
Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/971
Initiatives taken by health organizations for prevention of chronic diseases and introduction of rapid diagnostic tests is expected to propel the market growth
In 2017, Naugatuck Valley Women’s Health Specialists (NVWHS) decided to form a free informational program for heart health with Boston Heart Diagnostics. The program would include treatment and diagnosis of cardiovascular diseases (CVD), and improving women’s heart health. This program is expected to create awareness of CVD related diseases among women.
In 2017, Mission Hope Cancer Center accredited by the National Accreditation Program for Breast Cancer Centers (NAPBC) joined Dignity Health Central Coast hospitals. In Mission Hope’s cancer care program. The breast cancer examination service and facility is expected to be provided to women. Moreover, in 2017, Dignity Health installed 3D imaging technology – Mammography in the central coast. This technology helps in detection of breast cancer before symptomatic stage, which increases 98% survival rate. Thus, this program is expected to create more awareness and early detection of cancer, which in turn is expected to augment the growth of women’s health diagnostic test market.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/971
In 2016, Aeon Clinical Labs launched a RUO women’s health panel test, which is developed by Thermo Fischer Scientific. This test is based on PCR that detects 34 different target diseases including candidiasis, bacterial vaginosis, and sexually transmitted diseases such as gonorrhea, chlamydia, and some others. Aeon is further aiming to expand genetic assays for pharmacogenomics and hereditary cancer in the near future.
Some of the major factors hampering the market growth include high price of diagnostic imaging system and its related procedure.
Increasing prevalence of chronic diseases among women and rising awareness program is expected to fuel the growth of women’s health diagnostic test market
According to National Cancer Institute (NCI), in 2016, around 22,280 women were diagnosed with ovarian cancer and around 14,240 women succumbed to it in U.S. Furthermore, according to Cancer Research UK, in 2014, around 7,378 new cases of ovarian cancer, and around 55,222 cases of breast cancer were diagnosed in the U.K. Moreover, around 20 cases of ovarian cancers are diagnosed every day and are projected to increase by 15% in 2035.
Increasing incidence and prevalence of chronic diseases among women and demand for accurate and precise diagnostics are the major factors that are expected to augment the growth of the women’s health diagnostics market during the forecast period.
Organizations and foundations such as the National Breast Cancer foundation, World Health Organization, and National Institute of Health and Family Welfare (NIHFW) are conducting breast cancer awareness programs at local, state, and national levels, which is expected to fuel growth of the market during the forecast period.
Furthermore, according to the Centers for Disease Control and Prevention (CDC), in 2015, around 3,978,497 babies were born. This indicates an increase in pregnancy rates, which has generated demand for various gestation and fertility tests and treatments. Such factors are expected to propel growth of the women’s health diagnostic test market in the near future.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/womens-health-diagnostic-test-market-971
Some of the key players operating in the global women’s health diagnostic test market include Biomerieux SA, F. Hoffmann-LA Roche AG, Becton, Dickinson and Company, Siemens AG, Abbott Laboratories, Hologic, Inc., Koninklijke Philips N.V., Quest Diagnostics Inc., GE Healthcare, and Alere Inc.
Key Developments in Women’s Health Diagnostic Test Market
- In May 2019, Qiagen N.V. launched the first U.S. FDA-approved companion diagnostic test, Therascreen PIK3CA Kit, for identifying breast cancer.
- In January 2019, Nurx Inc. launched At-Home HPV Test Kits to detect the types of human papillomavirus (HPV) that are commonly found in cervical cancer.
- In September 2018, Mira, a part of Quanovate Tech Inc., launched Mira Fertility system personalized cycle prediction by measuring fertility hormone concentrations in urine samples. The devices also helps the women to know their fertility status.
- In December 2017, Inito, a medical technology start-up, launched a fertility monitor that helps women to track their ovulation days at home in an easy and convenient way. The single portable device uses smartphones to perform lab-grade medical diagnostic tests at home.
- In September 2017, GE Healthcare received U.S. FDA 510 (k) clearance for it’s first-ever mammography system. The device allows women to manage their own compression during the mammography exam with the help of company’s proprietary Senographe Pristina Dueta, a remote control.
Women’s Health Diagnostic Test Market Taxonomy:
- Ovarian Cancer Test
- Diagnostic Imaging Tests
- Ovarian Cancer Tumor Marker Test
- Breast Cancer Test
- Breast Cancer Tumor Marker Test
- Blood Chemistries and Blood Cell Count Test
- Osteoporosis Test
- Bone Densitometry
- In Vitro Blood Test
- Cervical Cancer Test
- PAP Smear
- HPV Test
- Pregnancy and Fertility Test
- Lab-Based Test
- Fertility Monitors
- Pregnancy Testing and Ovulation Prediction Kits
- Ultrasound Test
- Breast Imaging
- Obstetrics/ Gynecology Imaging
- Prenatal Genetic Screening and Carrier Test
- Cystic Fibrosis
- Torch Infections
- Down Syndrome and Edwards Syndrome
- Infectious Disease Test
- MRSA Test
- Hepatitis Test
- Tuberculosis Test
- Urinary Tract Infection Test
- Sexually Transmitted Disease (STD) Test
- HIV Test
- Chlamydia Trachomatis and Neisseria Gonorrhoeae Test
By End-use Industry:
- Diagnostic Laboratories
- North America
- Latin America
- Asia Pacific
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire